Probody® therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment by localizing treatment in the tumor and limiting activity in healthy tissue. We design Probody therapeutics to mask its target binding region. This mask reduces activity and toxicity in healthy tissue. Our novel therapeutics take advantage of the high levels of protease activity in the tumor microenvironment. Their target-binding regions are masked to limit activity —and toxicity— in healthy tissue. When Probody therapeutics encounter active proteases near tumor tissue, the mask is designed to be removed so that the unmasked therapeutic can bind to the tumor target.
We believe our Probody therapeutics have the potential to:
More information about protease biology can be found in our fact sheet.
Probody® therapeutics have been intentionally designed to bind selectively to tumors, and not to healthy tissue, with the goal of minimizing toxicity and creating safer, more effective cancer therapies. This revolutionary approach and our Probody drug candidates are designed based on a deep understanding of tumor protease biology.
Our highly versatile Probody® platform has potential utility across the most compelling antibody therapeutic modalities: Immunotherapies, antibody drug conjugates, T-cell-engaging bispecifics, and cytokine therapy. We are tackling big challenges with these modalities:
Data for our Probody® platform and therapeutics has been published in peer-reviewed articles and presented at medical and scientific congresses.